Further, Khan et al. found fisetin (10-60 μM) treatment resulted in activation of apoptosis, poly (ADP-ribose) polymerase (PARP) cleavage, modulation of Bcl-2 family protein expression (Bak, Bad, Bid, Bcl-xL), inhibition of the phoshoinositide 3-kinase (PI3K)/Akt signaling pathway, and activation of caspase 3, caspase-9, and-8 enzyme activity in LNCaP prostate cancer cell lines [53]. This evidence concerns the gene BCL2 and Familial prostate cancer.